Skip to main content

Table 3 Multivariable Cox proportional hazards model

From: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Variable Progression-free survival Overall survival
  Hazard ratio (95% CI) Pvalue Hazard ratio (95% CI) Pvalue
HR+ vs. HR- 0.63 (0.46 to 0.86) 0.003 0.51 (0.34 to 0.79) 0.002
HER-2 amplified/overexpressed vs. HER-2 normal 0.52 (0.34 to 0.79) 0.002 0.39 (0.21 to 0.73) 0.003
Visceral vs. other metastases 1.39 (0.92 to 2.05) 0.095 1.77 (0.95 to 3.30) 0.074
Number of metastatic sites (1 vs. 3 vs. ≥ 3) 0.88 (0.70 to 1.10) 0.266 0.67 (0.47 to 0.95) 0.024
Circulating tumor cells (< 5 versus ≥ 5) 0.58 (0.43 to 0.79) < 0.001 0.40 (0.26 to 0.62) < 0.001
  1. CI, confidence interval; HER-2, human epidermal growth factor receptor-2; HR+, estrogen receptor-positive and/or progesterone receptor-positive; HR-, both estrogen receptor-positive and progesterone receptor-negative.